Ambroxol therapy improve Symptoms in Gaucher disease patients: JAMA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-07-03 14:30 GMT | Update On 2023-10-21 08:43 GMT

Ambroxol proved safe to use over the long term and was related with patient improvement in Gaucher disease (GD) patients, says an article published in the Journal of American Medical Association.

In 2009, it was discovered that ambroxol improved the stability and lingering activity of a number of misfolded glucocerebrosidase variants. As a result, this study was carried out by Xia Zhan and colleagues to evaluate the hematologic and visceral results, biomarker changes, and safety of ambroxol medication for patients with Gaucher disease (GD) who were not receiving disease-specific treatment.

From May 6, 2015, to November 9, 2022, patients with GD who could not afford enzyme replacement treatment were recruited and administered oral ambroxol at the Shanghai, China-based Xinhua Hospital, which is connected with Shanghai Jiao Tong University School of Medicine. A total of 32 GD patients were included. 28 of the patients underwent follow-up for a period of time greater than six months; 4 were disqualified owing to loss of follow-up. Data analysis was carried out between May 2015 and November 2022. In a genetic metabolism centre, ambroxol-treated GD patients were monitored. Hematologic parameters, liver and spleen volumes, and biomarkers of chitotriosidase activity and glucosylsphingosine level were assessed at baseline and at various intervals throughout the ambroxol therapy.

The key findings of this study were:

1. Ambroxol was administered to a total of 28 patients for a mean (SD) of 2.6 (1.7) years.

2. Clinical response was seen in the remaining 26 individuals, but two patients with severe symptoms at baseline had worsening of hematologic parameters and biomarkers and were labelled nonresponders.

3. The mean (SD) haemoglobin concentration increased from 10.4 (1.7) to 11.9 (1.7) g/dL after 2.6 years of ambroxol therapy, while the mean (SD) platelet count increased from 69 (25) to 78 (30) 103/L.

4. The mean (SD) liver volume fell from 1.90 (0.44) to 1.50 (0.53) MN, while the mean (SD) spleen volume decreased from 17.47 (7.18) to 12.31 (4.71) multiples of normal (MN).

5. The biomarker median percentage changes from baseline were 34.1% for glucosylsphingosine level and 43.1% for chitotriosidase activity.

6. According to the age at which they began treatment, patients were divided into subgroups.

7. Those who started treatment earlier saw more rapid improvements: hemoglobin concentration increased by 16.5%, platelet count increased by 12.0%, whereas chitotriosidase activity decreased by 64.0% and glucosylsphingosine level decreased by 47.3%. There were three minor and brief adverse effects among the 28 individuals.

Reference:

Zhan, X., Zhang, H., Maegawa, G. H. B., Wang, Y., Gao, X., Wang, D., & Li, J. (2023). Use of Ambroxol as Therapy for Gaucher Disease. In JAMA Network Open (Vol. 6, Issue 6, p. e2319364). American Medical Association (AMA). https://doi.org/10.1001/jamanetworkopen.2023.19364

Article Source : JAMA Network Open

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Jacinthlyn Sylvia

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Ambroxol therapy improve Symptoms in Gaucher disease patients: JAMA

Similar News

Lung TB: Higher dose of rifampicin safe, can boost recurrence-free survival, says ICMR study

Nerandomilast Could Reduce Progressive Pulmonary Fibrosis: Study

JAPI Releases Dedicated Supplement Addressing Clinical Needs for Adult Vaccination in India

No Significant Protective Effect of Vitamin D Supplements Against Respiratory Infections: Lancet

COVID-19 Infection tied to elevated VTE Risk in Pregnancy and Postpartum period: Study

Switch to Dry-Powder Inhalers Tied to Higher ED Visits and Hospitalizations in COPD and Asthma Patients: JAMA

Rheumatoid Arthritis-Linked Lung Disease Significantly Raises Risk of Death, Finds Study

Pediatric pulmonary arterial hypertension Deaths Drop by 58 Percent, But India Remains Worst-Hit: Study Reveals